People with diabetes, particularly severe diabetes, tend to lose less weight with GLP-1s than people without diabetes, so microdosing is less likely to be as effective, though their dose should only be increased as they tolerate it. George said that in her professional opinion, microdosing is a potential option for patients with smaller amounts of weight to lose or as a bridge to start, or wean off, regular GLP-1 medications
Diabetologia 66(10):18691881 Chuang MH, Chen JY, Wang HY, Jiang ZH, Wu VC (2024) Clinical outcomes of Tirzepatide or GLP-1 receptor agonists in individuals with type 2 diabetes
However, typical gastrointestinal side effects associated with GLP-1 agents remain
Special Populations and Considerations Certain subgroups of adolescents may derive particular benefit from GLP-1 RA therapy or require special consideration